Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program

Table 3 Individual SF-36 scores at baseline and EOS post-treatment

SF-36 scales	Baseline Median (IQR) N = 10	EOS Median (IQR) N = 9	P-value	Effect size (ES)
PF	42.5 (35.0–55.0)	100.0 (90.0–100.0)	0.0039**	0.91
PH	12.5 (0.00–25.0)	100.0 (100.0–100.0)	0.0039**	0.91
EP	16.7 (0.00–33.3)	100.0 (100.0–100.0)	0.0078**	0.84
E/F	25.0 (25.0–35.0)	80.0 (75.0–80.0)	0.0039**	0.91
EWB	58.0 (36.0–72.0)	88.0 (84.0–92.0)	0.0039**	0.91
SF	50.0 (25.0–62.5)	100.0 (75.0–100.0)	0.0078**	0.84
P	45.0 (45.0–67.5)	100.0 (90.0–100.0)	0.0039**	0.91
GH	32.5 (10.0–50.0)	70.0 (60.0–80.0)	0.0078**	0.84

PF role limitations due to physical functioning, PH role limitations due to physical health, EP role limitations due to emotional problems, E/F energy/fatigue, EWB emotional well-being, SF social functioning, P pain, GH general health, N number of subjects, EOS end of study, IQR inter-quartile range
^**P < 0.01 (Wilcoxon signed-rank test). ES = Effect Size (Rosenthal’s formula with N = 10 subjects)

ISSN: 1757-6512